Biology of Prostate Cancer

项目总结(见说明)： 基梅尔癌症中心(KCC)的前列腺癌(BPC)计划是一个新的计划，它源于以前的内分泌机制和激素在癌症中的作用(EMHAC)计划，并代表了EHMAC中专注于前列腺癌的部分。从2007年到2011年，EMHAC增加了研究乳腺癌/妇科恶性肿瘤或前列腺癌/泌尿生殖系癌症的高效调查人员的数量，从而使2011年BPC计划的战略创建成为可能。在此期间 在同一时期，大费城前列腺癌工作组由新招募的Karen Knudsen博士创立，并作为BPC和相关财团发展的基础。BPC项目由来自10个部门和3个机构的18名调查人员组成。该计划目前每年从NCI拨款中获得230万美元的总成本，以及每年410万美元的同行审查总成本。 自2007年以来，该方案制作了343份出版物，其中10%是方案内出版物，43%是方案间出版物，5%既是方案间出版物，也是方案内出版物。Karen E.Knudsen博士(Leader)是一位在前列腺癌基础和转化性研究方面拥有专业知识的有成就的研究人员。Gomella博士是BPC的联合负责人(TJU)，他提供泌尿生殖系统恶性肿瘤的临床专业知识。法塔提斯博士是BPC(德雷克塞尔大学)的联合负责人，是一位成就卓著的内科科学家，在基础和临床层面上拥有癌症转移方面的专业知识。他将在BPC计划中发挥关键作用，整合德雷克塞尔大学和TJU癌症研究人员。 BPC计划的目标是利用泌尿生殖系统肿瘤学(尤其是前列腺癌)方面的重要翻译和临床专业知识，目的是：描绘前列腺癌发生和发展的基础机制，确定治疗晚期疾病的新方法，并通过将这些发现转化为临床试验来改善疾病管理。该计划内的研究旨在开发有效检测、诊断和治疗的新策略。 该计划的具体目标是：1.开发早期前列腺癌的预防、检测和分型的新策略；2.明确激素在恶性疾病发展和前列腺癌进展中的作用；3.开发前列腺癌的新治疗策略；4.为合理的治疗方案开发预测性标记物。

PROJECT SUMMARY (See instructions): The Blology of Prostate Cancer (BPC) Program at the Kimmel Cancer Center (KCC) is a new program that emanated from the former Endocrine Mechanisms and Hormone Action in Cancer (EMHAC) Program, and represents the section of the EHMAC that focused on prostate cancer. From 2007 to 2011, EMHAC increased the number of highly productive investigators studying either breast/gynecological malignancies or prostate/genitourinary cancers, allow^ing the strategic creation of the BPC program in 2011. During this same interval, the Greater Philadelphia Prostate Cancer Working Group was founded by new recruit Dr. Karen Knudsen, and served as a basis for development of the BPC and the associated consortium. The BPC program consists of 18 investigators from 10 departments and 3 institutions. The Program currently brings in $2.3 million/year in total costs from NCI grants and $4.1 million/year total peer-reviewed costs. Since 2007, the program produced 343 publications of which, 10% of publications were intra-programmatic, 43% were inter-programmatic, and 5% were both inter- and intra-programmatic. Dr. Karen E. Knudsen (Leader) is an accomplished investigator with expertise in basic and translational prostate cancer research. Dr. Gomella, the Co-Leader (TJU) of BPC, provides clinical expertise in genitourinary malignancies. Dr. Fatatis the Co-leader (Drexel University) of BPC is an accomplished physician scientist with expertise in cancer metastasis at the basic and clinical level. He will play a pivotal role integrating Drexel University and TJU cancer researchers in the BPC Program. The goals of the BPC program are to leverage the significant translational and clinical expertise in genitourinary oncology (most especially with regard to prostate cancer) with the intent to: delineate the mechanisms that underpin prostate cancer development and progression, identify novel means to treat advanced disease, and improve disease management by translating these findings into clinical trials. Studies within the program are directed at developing new strategies for effective detection,diagnosis,and cure. Specific aims of this program are to;1. Develop new strategies for prevention, detection, and subtyping of early stage prostate malignancies; 2. Define the impact of hormone action in malignant disease development and prostate cancer progression; 3. Develop novel treatment strategies for prostate malignancies;4. Develop predictive markers for rational therapy delivery.